[Fat emulsion tolerance in preterm infants of different gestational ages in the early stage after birth]

Hui Tang1, Chuan-Zhong Yang, Huan Li

  • 1Department of Neonatology, Shenzhen Maternity and Child Health Care Hospital Affiliated to Southern Medical University, Shenzhen, Guangdong 518028, China. yangczgd@163.com.

Insights

Extremely preterm infants have a reduced ability to metabolize long-chain fatty acids shortly after birth. These infants may not tolerate high-dose fat emulsions, unlike moderate-to-late preterm infants.

Area of Science:

  • Neonatalogy
  • Biochemistry
  • Pediatric Nutrition

Background:

  • Preterm infants require nutritional support, including fat emulsions, for growth and development.
  • Fat metabolism capacity varies with gestational age in neonates.
  • Understanding early fat emulsion tolerance is crucial for optimizing neonatal care.

Purpose of the Study:

  • To assess fat emulsion tolerance in preterm infants based on gestational age.
  • To investigate the relationship between gestational age and acylcarnitine profiles.
  • To determine optimal fat emulsion dosing in early neonatal periods for different preterm groups.

Main Methods:

  • 98 preterm infants categorized by gestational age: extremely preterm, early preterm, and moderate-to-late preterm.
  • Analysis of short-, medium-, and long-chain acylcarnitines using tandem mass spectrometry.
  • Comparison of acylcarnitine levels in umbilical cord blood and dried blood spots within 3 days post-birth, stratified by fat emulsion dose.

Main Results:

  • Extremely and early preterm infants showed lower long-chain acylcarnitines than moderate-to-late preterm infants, correlating positively with gestational age.
  • In extremely preterm infants, lower fat emulsion doses were associated with higher acylcarnitine levels on day 2.
  • No significant differences in acylcarnitine levels were observed between low- and high-dose fat emulsion subgroups in early and moderate-to-late preterm infants.

Conclusions:

  • Extremely and early preterm infants exhibit diminished long-chain fatty acid metabolism capacity within 3 days post-birth.
  • Early and moderate-to-late preterm infants appear to tolerate high-dose fat emulsions.
  • Extremely preterm infants may have impaired capacity to metabolize high-dose fat emulsions in the early neonatal period.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
387
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
392
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
293
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.0K